Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.

Conditions Studied

Interventions

  • DRUG Placebo
  • BIOLOGICAL IPN10200
  • BIOLOGICAL Dysport

Study Locations (20)

Other

  • Medical University Innsbruck, Department of Neurology — Innsbruck
  • Kepler University Hospital GmbH, Department of Neurology and Psychiatry — Linz
  • Brothers of Charity Hospital Linz, Department of Neurology I — Linz
  • Medical University Vienna, Department of Neurology — Vienna
  • Multiprofile Hospital for Active Treatment "Heart and Brain" — Pleven
  • Medical Center "Rusemed" EOOD — Rousse
  • Multiprofile Hospital for Active Treatment of Neurology and Psychiatry "Sveti Naum", Sofia, Neurological Diseases Clinic for Neurodegenerative and Peripheral Neurological Diseases — Sofia
  • Diagnostic Consulting Center - Convex EOOD — Sofia
  • Medical Center Medica Plus Ltd — Veliko Tarnovo
  • University Hospital Hradec Kralove, Clinic of Neurology — Hradec Králové
  • Hospital Jihlava, Department of Neurology — Jihlava
  • University Hospital Ostrava, Clinic of Neurology, Center for Demyelinating diseases — Ostrava
  • Regional Hospital Pardubice, Clinic of Neurology — Pardubice
  • University Hospital Kralovske Vinohrady, Clinic of Neurology — Prague
  • General University Hospital in Prague, Clinic of Neurology — Prague

California

  • Rancho Los Amigos National Rehab — Downey

Kansas

  • Kansas Institute of Research — Overland Park

Michigan

  • Quest Research Institute — Farmington Hills

Pennsylvania

  • Einstein Physical Medicine and Rehabilitation at Elkins Park — Elkins Park

Texas

  • The University of Texas Southwestern Medical Center — Dallas

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2021-04-29
Est. Completion 2027-10-30
Phase Phase 1

Sponsor

Ipsen

205 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04752774

The ClinicalTrials.gov registry entry for NCT04752774 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 205 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Spasticity appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04752774 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Other, California, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04752774 about?

NCT04752774 is a clinical study titled "A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.". The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper lim...

What is the current status of trial NCT04752774?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2021-04-29. Estimated completion is 2027-10-30.

What conditions does trial NCT04752774 study?

This clinical trial studies the following conditions: Spasticity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04752774?

The interventions under investigation include: Placebo (DRUG), IPN10200 (BIOLOGICAL), Dysport (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04752774?

This trial is sponsored by Ipsen, which has 205 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04752774 being conducted?

This trial has 20 study locations across California, Kansas, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial